US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency Jan 4, 2021
OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide Jan 4, 2021
Buffalo Bills and OPKO Health's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program Dec 31, 2020
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test Oct 20, 2020
OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools Oct 9, 2020
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency Oct 8, 2020
